NasdaqGS:SYRS

Stock Analysis Report

Executive Summary

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines.


Snowflake Analysis

Flawless balance sheet with limited growth.

Share Price & News

How has Syros Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SYRS's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

16.2%

SYRS

3.5%

US Biotechs

2.4%

US Market


1 Year Return

1.2%

SYRS

4.6%

US Biotechs

-10.0%

US Market

Return vs Industry: SYRS matched the US Biotechs industry which returned 1.9% over the past year.

Return vs Market: SYRS exceeded the US Market which returned -13.3% over the past year.


Shareholder returns

SYRSIndustryMarket
7 Day16.2%3.5%2.4%
30 Day4.4%-3.2%-11.0%
90 Day-5.6%-2.4%-19.4%
1 Year1.2%1.2%5.4%4.6%-8.1%-10.0%
3 Year-54.0%-54.0%19.3%16.3%17.3%9.6%
5 Yearn/a-4.4%-8.9%36.1%21.1%

Price Volatility Vs. Market

How volatile is Syros Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Syros Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

3.78x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate SYRS's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate SYRS's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: SYRS is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: SYRS is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SYRS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SYRS is overvalued based on its PB Ratio (3.8x) compared to the US Biotechs industry average (2.5x).


Next Steps

Future Growth

How is Syros Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

-1.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SYRS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SYRS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SYRS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SYRS's revenue (62.4% per year) is forecast to grow faster than the US market (7% per year).

High Growth Revenue: SYRS's revenue (62.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SYRS's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Syros Pharmaceuticals performed over the past 5 years?

-18.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SYRS is currently unprofitable.

Growing Profit Margin: SYRS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SYRS is unprofitable, and losses have increased over the past 5 years at a rate of -18.8% per year.

Accelerating Growth: Unable to compare SYRS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SYRS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22%).


Return on Equity

High ROE: SYRS has a negative Return on Equity (-95.27%), as it is currently unprofitable.


Next Steps

Financial Health

How is Syros Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: SYRS's short term assets ($114.5M) exceed its short term liabilities ($23.5M).

Long Term Liabilities: SYRS's short term assets ($114.5M) exceed its long term liabilities ($47.3M).


Debt to Equity History and Analysis

Debt Level: SYRS is debt free.

Reducing Debt: SYRS has no debt compared to 5 years ago when its debt to equity ratio was 0%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SYRS has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: SYRS has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of -22.8% each year.


Next Steps

Dividend

What is Syros Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SYRS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate SYRS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SYRS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SYRS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SYRS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.0yrs

Average management tenure


CEO

Nancy Simonian (58yo)

7.75s

Tenure

US$3,032,019

Compensation

Dr. Nancy A. Simonian, M.D., has been the Chief Executive Officer and President at Syros Pharmaceuticals, Inc. since July 2012. Dr. Simonian has served as a Director of Evelo Biosciences, Inc. Since April  ...


CEO Compensation Analysis

Compensation vs Market: Nancy's total compensation ($USD3.03M) is above average for companies of similar size in the US market ($USD1.49M).

Compensation vs Earnings: Nancy's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Nancy Simonian
President7.75yrsUS$3.03m1.6% $4.8m
Richard Young
Scientific Founder7yrsUS$149.31k0.91% $2.7m
Joseph Ferra
Chief Financial Officer2.08yrsUS$2.48mno data
David Roth
Chief Medical Officer4.33yrsUS$1.19mno data
Nathanael Gray
Scientific Founder & Member of Scientific Advisory Board7yrsno datano data
Eric Olson
Chief Scientific Officer7yrsno datano data
Gerald Quirk
Chief Legal & Administrative Officer and Secretary3.58yrsUS$1.46mno data
Naomi Aoki
Vice President of Corporate Communications & Investor Relationsno datano datano data
Christian Fritz
Head of Biologyno datano datano data
Jeremy Springhorn
Chief Business Officer2.42yrsUS$2.15m0.081% $241.5k

4.0yrs

Average Tenure

57yo

Average Age

Experienced Management: SYRS's management team is considered experienced (4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Nancy Simonian
President7.75yrsUS$3.03m1.6% $4.8m
Richard Young
Scientific Founder7yrsUS$149.31k0.91% $2.7m
Nathanael Gray
Scientific Founder & Member of Scientific Advisory Board7yrsno datano data
Peter Wirth
Chairman3.25yrsUS$179.31kno data
Phillip Sharp
Member of Scientific Advisory Board & Director7yrsUS$149.31k0.61% $1.8m
Amir Nashat
Independent Director4.25yrsUS$153.81kno data
Marsha Fanucci
Independent Director4.5yrsUS$154.74kno data
Gerard Evan
Member of Scientific Advisory Board7yrsno datano data
Scott Biller
Member of Scientific Advisory Board7yrsno datano data
Bradley Bernstein
Member of Scientific Advisory Boardno datano datano data

7.0yrs

Average Tenure

65yo

Average Age

Experienced Board: SYRS's board of directors are considered experienced (7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 23.2%.


Top Shareholders

Company Information

Syros Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Syros Pharmaceuticals, Inc.
  • Ticker: SYRS
  • Exchange: NasdaqGS
  • Founded: 2011
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$299.449m
  • Shares outstanding: 43.40m
  • Website: https://www.syros.com

Number of Employees


Location

  • Syros Pharmaceuticals, Inc.
  • 620 Memorial Drive
  • Suite 300
  • Cambridge
  • Massachusetts
  • 2139
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SYRSNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJun 2016
0S9DB (Deutsche Boerse AG)YesCommon StockDEEURJun 2016
0LC7LSE (London Stock Exchange)YesCommon StockGBUSDJun 2016

Biography

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients. It has target discovery, research collaboration, and option agreement with Incyte to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co., Ltd. for the development and commercialization of SY-1425. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/07 16:41
End of Day Share Price2020/04/06 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.